Astellas furthers oncology ambitions with $765 million Medivation deal
This article was originally published in Scrip
Executive Summary
Astellas has acquired global rights to Medivation's investigational prostate cancer drug MDV3100, in an alliance worth up to $765 million in up-front and milestone payments to the US firm.